# Pulmonary Vein Isolation Versus Botulinum Toxin Injection Plus Pulmonary Vein Isolation in Patients With Atrial Fibrillation

> **NCT02002923** · PHASE2 · UNKNOWN · sponsor: **Meshalkin Research Institute of Pathology of Circulation** · enrollment: 160 (estimated)

## Conditions studied

- Paroxysmal Atrial Fibrillation
- Persistent Atrial Fibrillation

## Interventions

- **PROCEDURE:** Pulmonary vein isolation
- **DRUG:** Botulinum Toxin

## Key facts

- **NCT ID:** NCT02002923
- **Lead sponsor:** Meshalkin Research Institute of Pathology of Circulation
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-06
- **Primary completion:** 2015-06
- **Final completion:** 2015-12
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2015-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02002923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02002923, "Pulmonary Vein Isolation Versus Botulinum Toxin Injection Plus Pulmonary Vein Isolation in Patients With Atrial Fibrillation". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT02002923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*